U.S. Markets closed

Navidea Biopharmaceuticals, Inc (NAVB)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.4750.000 (0.000%)
At close: 4:02PM EDT
People also watch
IMUCCLSNGALEMSTXTHLD
  • I bought in on 8/14/012. @ 3.58 (Neoprobe).. regrettably with some of my kids savings thinking it was promising. That is down 84% Now Goldberg wants to blame shareholders for not approving the dumbest idea ever . Please. Get off your bum and promote this where you still have the rights. Good job ...down 84%..
  • how is it , that we were down two cents in pre market , and now we are up
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • I'm officially bowing out from this company! Not enough movement and should be much higher and it's still crumbling because of this poor #$%$ mgmt! Glta!!
  • We need a positive run today. 🙏 glta
  • Need management to make some positive decisions. I would have supported a reverse split of 10 to 1. That would make it close to a $5 stock. Then they could split the company. Come on management start earning your pay.
  • Sayre Therapeutics article ET Healthworld by CEO Shukrit Shimote dated Jly 15, 2017 wrote about areemement for the exclusive license and NAVB for development and commercialization of Tc 99m Tillmanocept in India. Mr Chimote 10 million cases in INDIA and expected to may come close to 20,000,000 cases by 2025.. very interesting. check out these many articles HEALTHWORD NEWS FROM ECONOMIC TIMES!!!
  • Now another PR disaster ===getting robbed by a PI firm while investigating each other. Never a reverse split. I want all my shares to go up a buck not 1/20th of them. So they get a reverse split and then the officers, MG and the board get the same number of scoops full of free shares and sell them at $5??? Never--- if they ever reverse split they should always be required to sell their shares at 1/20th of their worth!!! that should get these freeloaders hustling. And lets say they are promised 20K shares at a milestone in the future and the reverse split has those share then worth $5 at that time. No way!!! Their milestone number of gift shares promised is reduced 1/20th as soon as they get a RS or they get 1/20th of the PPS. We can get robbed by CRG, PI firms but the Directors and Officers want to make themselves immune as they concoct more ways to rob us while the sales languish. They are churning us. We need to have a compensation committee that isn't inbred. FYI-- with NAVB since 2000.
  • Another article quoting MG?
    "Navidea CEO: Splitting company could boost struggling stock". Remember when MG stated when he took over that they'd communicate more frequently w shareholders? Now he seems afraid to and only speaks through his local newspaper. Get on the phone and answer shareholder questions MG!
  • [!] Freshly upgraded to now display all possible spread combinations - Option spread traders have a look at CreditSpreads.io, cost free live list of mathematically gainful option credit spreads for the upcoming four weeks, sometimes including spreads for NAVB! High probability option credit spreads offer a way to invest with determined risk and the max profit gained up front. CreditSpreads.io targets solely the option spreads which meet its stringent standards for probability and profit, and ensures sustained profitability by telling you of any upcoming events which can affect the trade. http://creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    creditspreads.io
  • I would love to sell the company for 2.25 pps!! Good luck to all!! 🙏
  • This Goldberg better watch himself and what he says. He's acting childish and greddy.
  • perfect example of a robed reversed split is ARNA ARENA PEAKED AND NOW HEADING BAK DOWN
  • does the CEO really want t know how to get the price up? If he doesn't know then that is the problem. He needs to go. Quit screwing up --like with CRG--- and start making money. You don't get the price up with smoke and mirrors tricks like RS. That in today's lingo is fake PPS. No one in retail will buy the stock at 50 cents so why would you think they would at $8? All RS does is pump it up quick so that with no more news or profit it slides right back down. Then shareholders who have been loyal during all of these chain reaction management screw ups eventually wind up with 1000 shares at 50 cents instead of 20K shares. That is why we didn't let you do it.

    if you can't figure out how to do your job right without voodoo tricks you need to go, MG.
  • We cant make money with THIS ONE stock. How the hell are we gonna make money with TWO???@#$%^%$&*
  • [!] Recently upgraded to now display all available spreads - Option traders have a look at CreditSpreads.io, totally free live list of statistically gainful option credit spreads for the coming four weeks, sometimes including spreads for NAVB! High probability option credit spreads provide a solution to trade with specified risk and the max profit received right away. CreditSpreads.io lazer-targets solely the credit spreads which fulfill its stringent criteria for risk and profit, and ensures continued profitability by warning you of any future catalysts which could affect the trade. http://creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    creditspreads.io
  • We need something here
  • "Splitting into two companies would leave shareholders with stock in each without diluting their positions, CEO Michael Goldberg said".

    How does that happen? Obviously the spin off could be 20 for 1 to be a $5 stock, but what's left at NAVB a two bit stock? I think MG will figure out some way to screw the shareholders as pay back for the no vote.
  • why are we going down on very low volume.
    are people afraid to sell
    or d they think that we are near the end of the rainbow
  • this company is depressing ! Goldberg you need to go! Jed Latkin stay, we like you!